English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/167049
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:

Title

Dysfunctional Skin-Derived Glucocorticoid Synthesis Is a Pathogenic Mechanism of Psoriasis

AuthorsHannen, R.; Udeh-Momoh, C.; Upton, J.; Wright , M.; Michael, A.; Gulati, A.; Rajpopat, S.; Clayton, N.; Yeo, L.; Halsall, D.; Burrin, J.; Flower, R.; Sevilla, Lisa M. ; Latorre, V.; Frame, J.; Lightman, S.; Pérez, Paloma ; Philpott, M.
Issue DateAug-2017
PublisherElsevier
CitationJournal of Investigative Dermatology 137(8):1630-1637 (2017)
AbstractGlucocorticoids (GC) are the primary steroids that regulate inflammation and have been exploited therapeutically in inflammatory skin diseases. Despite the broad-spectrum therapeutic use of GC, the biochemical rationale for locally treating inflammatory skin conditions is poorly understood, as systemic GC production remains largely functional in these patients. GC synthesis has been well characterized in healthy skin, but the pathological consequence has not been examined. Here we show de novo GC synthesis, and GC receptor expression is dysfunctional in both nonlesional and lesional psoriatic skin. Use of GC receptor epidermal knockout mice with adrenalectomy allowed for the distinction between local (keratinocyte) and systemic GC activity. Compensation exhibited by adult GC receptor epidermal knockout mice demonstrated that keratinocyte-derived GC synthesis protected skin from topical phorbol 12-myristate 13-acetate-induced inflammatory assault. Thus, localized de novo GC synthesis in skin is essential for controlling inflammation, and loss of the GC pathway in psoriatic skin represents an additional pathological process in this complex inflammatory skin disease.
Description8 Pages, 4 Figures
Publisher version (URL)http://dx.doi.org/10.1016/j.jid.2017.02.984
URIhttp://hdl.handle.net/10261/167049
DOI10.1016/j.jid.2017.02.984
ISSN0022-202X
E-ISSN1523-1747
Appears in Collections:(IBV) Artículos
Files in This Item:
File Description SizeFormat 
2017 J Invest Dermatol 137-1630.pdfVersión Pre-Print del artículo291,77 kBAdobe PDFThumbnail
View/Open
2017 J Invest Dermatol 137-1630-Fig1.pdfFigura 12,44 MBAdobe PDFThumbnail
View/Open
2017 J Invest Dermatol 137-1630-Fig2.pdfFigura 23,21 MBAdobe PDFThumbnail
View/Open
2017 J Invest Dermatol 137-1630-Fig3.pdfFigura 37,2 MBAdobe PDFThumbnail
View/Open
2017 J Invest Dermatol 137-1630-Fig4.pdfFigura 41,63 MBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.